What is the significance of a positive rapid plasma reagin (RPR) test and how should it be evaluated and managed?

Positive RPR Test: Evaluation and Management

A positive RPR test requires immediate confirmation with a treponemal test (FTA-ABS or TP-PA) to distinguish true syphilis infection from biological false positives, followed by stage-specific treatment with benzathine penicillin G based on clinical and serologic findings.

Initial Diagnostic Approach

When you encounter a positive RPR, you must:

• Confirm with treponemal testing (FTA-ABS or TP-PA) - RPR alone is insufficient because false positives occur with various medical conditions 1
• Obtain quantitative RPR titer - this correlates with disease activity and guides treatment monitoring 2, 1
• Perform clinical examination looking for:
  • Primary syphilis: genital/oral ulcers or chancres
  • Secondary syphilis: rash (especially palms/soles), mucocutaneous lesions, lymphadenopathy, condyloma lata
  • Tertiary manifestations: cardiac, neurologic, ophthalmic, auditory symptoms, or gummatous lesions 1

Understanding False Positives

Biological false positive RPR occurs in approximately 1-2% of the general population and is associated with:

• Autoimmune diseases (particularly lupus anticoagulant and positive ANA) 3
• Pregnancy
• Recent vaccination
• Acute viral infections
• Chronic liver disease

Women with false positive RPR are significantly more likely to have lupus anticoagulant, positive ANA (especially ≥1:320), and anticardiolipin antibodies 3. Consider rheumatologic workup if treponemal tests are negative.

Staging and Treatment Algorithm

If Both RPR and Treponemal Tests Are Positive:

Stage determination is critical because it dictates treatment duration:

1. Primary Syphilis (chancre present, recent exposure <90 days):

   • Benzathine penicillin G 2.4 million units IM single dose 4

2. Secondary Syphilis (rash, mucocutaneous lesions, lymphadenopathy):

   • Benzathine penicillin G 2.4 million units IM single dose 4

3. Early Latent Syphilis (asymptomatic, acquired within past year):

   • Benzathine penicillin G 2.4 million units IM single dose 4

4. Late Latent or Unknown Duration:

   • Benzathine penicillin G 2.4 million units IM weekly × 3 weeks 4

Special Populations Requiring Modified Approach

HIV-Infected Patients:

• Treat according to stage-specific recommendations above 4
• Consider CSF examination if: CD4 ≤350 cells/mL AND/OR RPR titer ≥1:32, though this hasn't improved clinical outcomes unless neurologic symptoms present 4
• Follow-up at 3,6,9,12, and 24 months (more frequent than HIV-negative patients) 4

Pregnant Women:

• All pregnant women must be screened at first prenatal visit 2, 1, 4
• High-risk populations: rescreen at 28 weeks and delivery 1, 4
• Treatment: stage-appropriate penicillin regimen 2, 1
• Some experts recommend second dose of benzathine penicillin 2.4 million units IM one week after initial dose for primary/secondary/early latent syphilis in pregnancy 2, 1
• Critical pitfall: Risk of Jarisch-Herxheimer reaction causing premature labor/fetal distress in second half of pregnancy - counsel patients to seek care immediately if contractions or decreased fetal movement 2, 1

Neurosyphilis Suspected (neurologic symptoms, ocular symptoms, auditory symptoms):

• Immediate CSF examination required 4, 2
• CSF findings: elevated WBC (>5/mm³), elevated protein, reactive VDRL-CSF 2, 1
• Treatment: aqueous crystalline penicillin G or procaine penicillin (see neurosyphilis guidelines)

Post-Treatment Monitoring

Follow-up serologic testing is mandatory to assess treatment response:

• HIV-negative patients: Clinical and serologic evaluation at 6 and 12 months 4
• HIV-positive patients: Evaluate at 3,6,9,12, and 24 months 4

Defining Treatment Success vs. Failure

Treatment success = fourfold (2-dilution) decline in RPR titer (e.g., 1:32 → 1:8) 2, 1

Treatment failure indicators:

• Clinical symptoms persist or recur
• Sustained fourfold increase in nontreponemal titer
• Failure to achieve fourfold decline within 6-12 months for early syphilis or 12-24 months for late syphilis 4, 1, 5

Management of treatment failure: CSF examination and retreatment 4, 1

The Serofast Phenomenon

Important caveat: 15-25% of patients maintain low-level positive RPR titers indefinitely despite adequate treatment (serofast state) 2, 1. This is more common with:

• Older age 5
• Late latent syphilis
• Lower baseline RPR titers
• HIV infection 6

Serofast patients do NOT routinely need retreatment unless clinical symptoms develop or titers rise fourfold 5.

Critical Technical Considerations

RPR testing has significant limitations:

• Use the same test method (VDRL vs. RPR) and preferably same laboratory for serial monitoring - RPR titers run slightly higher than VDRL and cannot be directly compared 2, 1
• Interlaboratory variability can reach 3-fold differences in titers, potentially leading to inappropriate treatment decisions 7
• Spontaneous titer fluctuations occur: RPR can decrease >4-fold in 10% of untreated patients within 1-3 months, and this spontaneous decrease predicts slower post-treatment decline 8
• Seroreversion to negative occurs in only 42% of treated patients, taking median 235 days, and is less likely with HIV infection or repeat infections 6

Penicillin Allergy

For penicillin-allergic patients whose compliance cannot be ensured: desensitization followed by penicillin treatment is strongly recommended 1, 4. Alternative regimens (doxycycline, ceftriaxone) are less well-studied, particularly in HIV-infected patients 4.

Pregnancy with penicillin allergy: Desensitization is mandatory - no acceptable alternatives exist for preventing congenital syphilis 2, 1.